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Nesiritide and clinically 
relevant outcomes in 
cardiac surgery: 
a meta-analysis of 
randomized studies
ABSTRACT
B-type natriuretic peptide is a cardiac hormone that relaxes vascular smooth muscle and causes arterial dilatation. Nesiritide 
has been  associated with increased urine output; reduced diuretic requirements; and suppression of aldosterone, endot-
helin, and norepinephrine. We have independently conducted the first systematic review and meta-analysis of randomized 
trials to determine the impact of nesiritide on renal replacement therapy and death in patients undergoing cardiac surgery. 
We performed a meta-analysis of 6 randomized controlled studies including 560 patients (280 receiving nesiritide and 280 
assigned to the control group). Two unblinded reviewers selected randomized trials studying  nesiritide  in patients undergoing 
cardiac surgery. Nesiritide doses ranged from 0.005 mcg/kg/min to 0.01 mcg/kg/min. Nesiritide did not reduce postoperative 
creatinine peak values: -0.16 [-0.42, 0.10], p for effect=0.23, p for heterogeneity<0.01, I2=90.5%) or the need for  renal 
replacement therapy (1/177 in the nesiritide group vs 4/176 in the control group OR 0.39 [0.07, 2.06], p for effect=0.27, p for 
heterogeneity=0.70, I2=0%). We observed an interesting trend toward a reduction in mortality in the nesiritide group:13/280 
(4.6%) vs 22/280 (7.8%) OR 0.57 [0.28, 1.15], p for effect=0.12, p for heterogeneity=0.43, I2=0%. Nesiritide did not reduce 
time of mechanical ventilation -8.77 hours [-21.42, 3.88], p=0.17, length of hospital stay -2.67 days [-6.50, 1.16], p=0.17 or 
intensive care unit (ICU) stay -0.94 days [-2.83, 0.95], p=0.33. In conclusion, further randomized controlled trials are needed 
to support the hypothesis that nesiritide improves clinically relevant outcomes in cardiac surgery.
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Introduction
Acute renal failure is associated with 
significant morbidity and mortality rates. 
(1,2) Need for dialysis is an indepen-
dent risk factor for early mortality after 
complicated cardiac surgery. (3,4) The 
pathogenesis of postoperative acute 
renal failure is believed to be predomi-
nantly a consequence of renal hypoper-
fusion and ischemia, particularly of the 
renal medulla. (5) 
Several therapeutic strategies for pre-
serving renal function after cardiac sur-
gery have been investigated, (6-12) 
but to date none have been proven 
effective. 
Brain natriuretic peptide (BNP) is cur-
rently being investigated in the peri-
operative management of cardiac sur-
gery patients and may be especially 
beneficial for patients with ventricular 
dysfunction, pulmonary hypertension, 
or renal dysfunction. Measured BNP 
levels can be used to predict postop-
erative complications and the risk of 
further cardiac events in cardiac sur-
gery. (13-15)
Nesiritide is a recombinant B-type 
natriuretic peptide that is structurally 
identical to the endogenous hormone 
produced by the ventricle in response 
to increased wall stress, hypertrophy 
and volume overload. Nesiritide causes 
vasodilatation and may influence renal 
blood flow and natriuresis. It produces 
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Table 1.  features of included papers.
Author   Year  Paper   Surgical procedure Multicentric  
 
      
Mentzer RMJ[22]  2007  JACC   CABG+ mitral surgery yes
  
Chen HH[23]  2007  Circulation  CABG+ valvular  no  
        + ascending aorta
Sezai A [24]  2006  Circ J   CABG   no  
Sezai A[25]  2007  Circ J   CABG   no  
Hayashida N[26]  2000  Ann Thor Surg  mitral surgery  no 
Brackbill ML[27]  2007  Ann Pharmacotherapy CABG   no 






















2007[22] 1 - 1 - 1 3
Chen HH, 2007[23] 
1 - 1 - 1 3
Sezai A , 2006[24] 
1 - 1 - 1 3
Sezai A, 2007[25] 1 - 0 - 1 3
Hayashida N, 
2000[26] 1 1 0 - 1 2
Brackbill ML, 
2007[27] 1 - 0 - 1 3
Table 3. Preoperatory creatinine values and Nesiritide Perfusion values.
Author   Preop Crea Nesiritide Preop Crea Control  Nesiritide Bolus Nesiritide Perfusion
         (mcg/Kg)  (mcg/kg/min) 
        
Mentzer RMJ, 2007[22] 1,07+0,40  1,11+0,44  no  0.01
Chen HH, 2007[23]  1,7+0,5   1,7+0,7   no  0.005 
Sezai A , 2006[24]  -   -   no  0.02
Sezai A, 2007[25]  -   -   no  0.01
Hayashida N, 2000[26] -   -   no  0.05
 
Brackbill ML, 2007[27] 1,0+0,3   1,1+0,2   0,2  0.01
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dose-related reductions in pulmonary 
capillary wedge pressure (preload), 
right atrial pressure and systemic vas-
cular resistance and indirectly leads to 
increases in stroke volume and cardi-
ac output. (16) Nesiritide is currently 
approved in the US for the treatment of 
acute decompensated heart failure.
Numerous, apparently positive but 
inconclusive reports, targeted to surro-
gate end-points, have recently appeared 
in the literature on the use of nesiritide 
in subjects undergoing cardiac surgery. 
Nesiritide may even be associated with 
an increased risk of death when used 
for the treatment of patients with acutely 
decompensated heart failure. (17) To 
address the question whether nesiritide 
might influence patients’ outcome after 
cardiac surgery, we have independ-
ently conducted an updated systematic 
review and meta-analysis from existing 
trials to determine, for the first time, the 
impact of nesiritide on the perioperative 
need for renal replacement therapy and 
its impact on death in patients undergo-
ing cardiac surgery. 
Materials and methods
Search Strategy   Pertinent studies were 
independently searched in BioMedCen-
tral, CENTRAL, and PubMed (updated 
June 15, 2008) by two trained investiga-
tors. The full PubMed search strategy, 
including the  key-word, nesiritide, was 
developed according to Biondi-Zoccai et 
al. (18) and is available in the appendix. 
Recent (2006-2008) conference proceed-
ings, from the International Anesthesia 
Research Society, American Heart Asso-
ciation, American College of Cardiology, 
American Society of Anesthesiology and 
European Society of Cardiology, were 
hand searched. In addition, we employed 
backward snowballing (ie scanning of 
references of retrieved articles and perti-
nent reviews) and contacted international 
experts for further studies. No language 
restriction was enforced, and non-Eng-
lish-language articles were translated 
when appropriate.
References obtained from database 
and literature searches were first inde-
pendently examined at the title/abstract 
level by several investigators with diver-
gences resolved by consensus, and 
then, if potentially pertinent, retrieved as 
complete articles.
The following inclusion criteria were 
employed for potentially relevant stud-
ies: a) random allocation to treatment, 
b) comparison of nesiritide versus 
control or other treatment, c) patients 
undergoing adult cardiac surgery.
The exclusion criteria were: a) non-
parallel design (ie cross-over) random-
ized trials, b) duplicate publications (in 
this case only the article reporting the 
longest follow-up was abstracted), c) 
non-human experimental studies, and 
e) no outcome data.
Two investigators independently 
assessed compliance with  selection 
criteria and selected studies for the 
final analysis, with divergences finally 
resolved by consensus (table 1).
Baseline and outcome data were inde-
pendently abstracted by several investi-
gators with divergences resolved by con-
sensus. Specifically, we extracted study 
design (including patient selection and 
randomization), population, clinical set-
ting, the number of patients randomized, 
patients’ characteristics (preoperative 
creatinine), serum peak creatinine val-
ues, renal replacement therapy, adverse 
events, mechanical ventilation, inten-
sive care unit (ICU) stay, length of hos-
pital stay, death. At least two separate 
attempts at contacting original authors 
were made in case of missing data.
The primary end-point of our analysis 
was  in-hospital mortality. The co-prima-
ry endpoint was the number of patients 
progressing to acute kidney injury (AKI) 
requiring at least one episode of renal 
replacement therapy. Secondary end-
points included peak serum creatinine 
levels, mechanical ventilation and the 
duration of ICU and hospital stay.
The internal validity and risk of bias of 
included trials was appraised according 
to the Jidad score and by completing a 
risk of bias table. This was performed by 
two independent reviewers, with diver-
gences resolved by consensus (table 
2). Two independent and experienced 
reviewers also appraised study quality, 
with divergences resolved by consensus.
Binary outcomes from individual stud-
ies were analyzed  in order to compute 
individual relative risks (RR) with perti-
nent 95% confidence intervals (CI), and 
a pooled summary effect estimate was 
calculated by means of a fixed effects 
model, except in the case of at least 
moderate (50%) statistical inconsis-
tency (I2) when a random effect model 
was used. (19)
We assessed the robustness of find-
ings from the primary analysis through 
a series of sensitivity analyses, includ-
ing random effects model, and by with-
drawing one study at a time. Statistical 
heterogeneity and inconsistency was 
measured using, respectively, Cochran 
Q tests and I2. (20)
According to Higgings et al. I2 val-
ues around 25%, 50%, and 75% were 
considered representing respectively 
low, moderate and severe statistical 
inconsistency. The risk of small study 
bias (including publication bias) was 
assessed by visual inspection of funnel 
plots. Statistical significance was set 
at the two-tailed 0.05 level for hypoth-
esis testing and at 0.10 for heteroge-
neity testing. Unadjusted P values are 
reported throughout. Computations 
were performed with SPSS 11.0 (SPSS, 
Chicago, IL, USA), and RevMan 4.2 (a 
freeware available from The Cochrane 
Collaboration). (21)
This study was performed in compli-
ance with The Cochrane Collaboration 
and the Quality of Reporting of Meta-
Analyses (QUOROM) guidelines.
Results
Database searches, snowballing and 
contacts with experts yielded a total of 
9 citations. Excluding 3 non pertinent 
titles or abstracts, we retrieved six stud-
ies in complete form and assessed 
them  according to the selection crite-
ria, (22-27) which were included in the 
final analysis after the correspondent 
authors confirmed that there was no 
overlapping and/or duplicate publica-
tion. Five of these 6 studies were identi-
fied through database searches, while 
snowballing identified the sixth study. 
(24) Contact with experts and confer-
ence proceedings did not identify any 
further studies.
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Study Characteristics The six random-
ized controlled studies included 560 
patients (280 to nesiritide and 280 to 
the control group). All studies were per-
formed in adult patients undergoing 
cardiac surgery (table 1).
All studies were of relatively high quality, 
with a low or moderate risk of underlying 
bias (table 2). One study employed a 
multicenter design. (22) All studies report-
ed on mortality, while four of six stud-
ies reported data on renal replacement 
therapy, (23-25,27)  postoperative serum 
creatinine peak (22,24,25,27) and ICU 
stay. (22,25-27) Three studies reported 
data on length of hospital stay (22,25,27) 
and mechanical ventilation. (22,25,26)
Two studies used nesiritide (24,25) 
infusion for 12 hours, one study for six 
hours (26)  and other studies for at least 
24 hours. (22,23,27) Nesiritide doses 
ranged from 0.005 mcg/kg/min to 0.05 
mcg/kg/min. Brackbill et al. (27) used 2 
mcg/Kg of nesiritide as bolus (table 3).
Quantitative Data Synthesis Analysis 
showed that, in comparison to control 
treatment, nesiritide was not associated 
with clinically relevant benefits accord-
ing to our  major end points. Specifically, 
nesiritide did not reduce postoperative 
creatinine peak values: -0.16 [-0.42, 
0.10], p for effect=0.23, p for hetero-
geneity<0.001, I2=90.5%) (figure1). 
Nesiritide also did not reduce the need 
for  renal replacement therapy 1/177 
in the nesiritide group vs 4/176 in the 
control group OR 0.39 [0.07, 2.06], p for 
effect=0.27, p for heterogeneity=0.70, 
I2=0%) (figure 2). There was an interest-
ing trend toward a reduction in mortality: 
13/280 (4.6%) in the nesiritide group vs 
22/280 (7.8%) in the control group OR 
0.57 [0.28, 1.15], p for effect=0.12, p for 
heterogeneity=0.43, I2=0%) (figure3). 
Finally, nesiritide did not reduce time 
of mechanical ventilation -8.77 hours 
[-21.42, 3.88], p for effect=0.17, p for 
heterogeneity=0.05, I2=67.5%, (figure 
4) length of hospital stay -2.67 days 
[-6.50, 1.16], p for effect=0.17, p for 
heterogeneity<0.001 I2=85.6%, (figure 
5) and ICU stay -0.94 days [-2.83, 0.95], 
p for effect=0.33, p for heterogene-
ity=0.10, I2=51.5% (figure 6). Hypoten-
sion was reported by only Mentzer et al. 
(22) (one in the nesiritide group versus 
two in the control group). No significant 
side effect or adverse event was report-
ed by the uthors.
Discussion
The most important result of this meta-
analysis of six randomized controlled 
studies is that , in spite of promising 
initial reports on the beneficial effects 
of nesiritide,  there is still no evidence of 
improvement in clinically relevant out-
comes when using this drug. In particu-
lar, nesiritide does not reduce the need 
for renal replacement therapy, ICU stay, 
the length of hospital stay and the time 
of mechanical ventilation. Although no 
significant association between nesirit-
Figure 1. Individual and pooled estimates for peak postoperative serum 
creatinine (mg/dl).
Figure 2. Individual and pooled estimates for the risk for renal replacement 
therapy.
Figure 3. Individual and pooled estimates for the risk for mortality. 
Figure 4. Individual and pooled estimates for time on mechanical ventilation 
(hours).
 21www.signavitae.com
Figure 6. Individual and pooled estimates for intensive care unit (ICU) stay 
(days).
ide and mortality has been found in our 
study, a trend suggesting lower mortal-
ity rates for patients treated with nesirit-
ide was suggested. The 50% reduction 
in mortality observed in this meta-anal-
ysis, although statistically significant, 
could be of interest for further studies. 
Unfortunately, to demonstrate a reduc-
tion in mortality from 7.8 – 4.6 research-
ers have to plan a large trial of at least 
2000 patients. No systematic review 
regarding the efficacy of nesiritide in 
the specific setting of cardiac surgery 
has been published so far. This review 
is unique in looking at a meta analysis 
of neseritide in the post operative adult 
cardiac patient.
Natriuretic peptides belong to a family 
of  small proteins that play a major role 
in modulation of natriuresis, diuresis 
and vasodilatation. They counteract the 
activity of the renin-angiotensin-aldos-
terone system. They are also involved 
in the regulation of homeostasis, fat 
metabolism and long bone growth. 
Natriuretic peptides share a common 
17-amino-acid structure and have 
actions that are targeted at protect-
ing the cardiovascular system from the 
effect of volume overload. Secretion of 
the peptides is stimulated by atrial and 
ventricular distension, increased blood 
pressure, hypoxia or renal dysfunction. 
(16) Natriuretic peptides are systemic 
and renal vasodilators that also inhibit 
renal tubular sodium reabsorbtion and 
renin-angiotensin-aldosterone axis acti-
vation. (28) 
Nesiritide is the synthetic natriuretic 
peptide (recombinant BNP) which is 
approved for treatment of symptomatic 
acute decompensated heart failure. 
Nesiritide is a 32 amino acid peptide, 
similar to the naturally occurring BNP 
and when administred intravenously fits 
a two-compartment model with a rapid 
distribution half-life of 2 minutes. The 
haemodynamic effects of nesiritide, 
mainly consisting in the lowering of pul-
monary capillary wedge pressure, and 
systolic blood pressure, are observed in 
the first 15 minutes of an infusion. (29) 
In studies in which patients received 
standard congestive heart failure ther-
apy (diuretics, dopamine), nesiritide 
Figure 5. Individual and pooled estimates for length of hospital stay (days).
therapy lowered pulmonary capillary 
occlusion pressure and resolve dys-
pnea more rapidly than nitroglycerin 
and placebo. (30) Nesiritide showed 
a dose-dependent arterial and venous 
vasodilatation effect, mediated by 
the activation of cyclic guanosine 3-5 
monophosphate-coupled receptor 
NPR-A which is present in the endothe-
lium. (31) During nesiritide infusions, 
plasma aldosterone levels decrease, 
combined with increased urine output 
and sodium excretion. (32) Nesiritide 
improves symptoms in patients with 
acutely decompensated heart failure 
compared with placebo and appears 
to be safer than dobutamine. Its short 
term safety, relative to standard diuretic 
and vasodilator therapies, is less clear. 
Recently, a meta-analysis of outcome 
data from trials on acute decompen-
sated heart patients generated some 
controversy, (17) and further trials are 
needed to discern the effects of nesirit-
ide therapy on renal function. Wang DJ 
et al. demonstred that nesiritide infusion 
in decompensated heart failure patients 
does not improve renal function. (33)
BNP plasma levels can also be used as 
a marker of the presence of acute heart 
failure. It has been  demonstrated that 
BNP levels rise  when ventricle walls 
are dilated during acute heart failure. 
Elevated levels of BNP are not only pres-
ent during primary acute heart failure 
but may be related to secondary right 
heart failure in the case of pulmonary 
embolism, severe lung disease or an 
exacerbation of established systolic dys-
function resulting from other causes.
The NAPA trial was a multicenter ran-
domized, double-blind, placebo-con-
trolled trial of nesiritide versus placebo 
in 303 patients  with chronic left ven-
tricular dysfunction undergoing cardiac 
surgery. This study revealed that nesir-
itide infusion has a favorable short-
term effect on renal function. Patients 
receiving nesiritide had greater urine 
output, lower peak increase in serum 
creatinine levels in the immediate 
postoperative period compared with 
patients receiving placebo. (22) Chen 
et al. demonstrated that perioperative 
administration of low dose  nesiritide 
is biologically active and decreases 
plasma cystatin in patients with renal 
insufficiency undergoing cardiopul-
monary bypass cardiac surgery. (23) 
Intraoperative administration of nesir-
itide had potent effects on natriuresis 
and systemic vasodilatation by elevat-
ing cyclic guanosine monophosphate 
levels. Nesiritide can be useful for the 
management of haemodinamics and 
water-sodium retention after cardiopul-
monary bypass. (26)
Limitations. We analyzed data from six 
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studies which have different inclusion 
criteria. Therefore, patients included 
might have differed significantly in 
baseline clinical characteristics. Differ-
ent clinical conditions (such as renal 
dysfunction, heart failure, valvular 
defects), therapeutic protocols, and 
surgical scenarios may affect the effec-
tiveness of nesiritide.
Conclusions. Our meta-analysis dem-
onstrated that nesiritide is not yet an 
established method for the prevention 
of acute renal failure and mortality in 
cardiac surgery. Further randomized 
controlled studies are warranted.
APPENDIX
PubMed search strategy according to Biondi-Zoccai et al. (18) 
(nesiritide) AND (operatin* OR operativ* OR operation* OR interven* OR surger* OR surgic*) AND (randomized controlled trial[pt] OR 
controlled clinical trial[pt] OR randomized controlled trials[mh] OR random allocation[mh] OR double-blind method[mh] OR single-blind 
method[mh] OR clinical trial[pt] OR clinical trials[mh] OR (clinical trial[tw] OR ((singl*[tw] OR doubl*[tw] OR trebl*[tw] OR tripl*[tw]) AND 
(mask*[tw] OR blind[tw])) OR (latin square[tw]) OR placebos[mh] OR placebo*[tw] OR random*[tw] OR research design[mh:noexp] OR 
comparative study[tw] OR follow-up studies[mh] OR prospective studies[mh] OR cross-over studies[mh] OR control*[tw] OR prospectiv*[tw] 
OR volunteer*[tw]) NOT (animal[mh] NOT human[mh]) NOT (comment[pt] OR editorial[pt] OR meta-analysis[pt] OR practice-guideline[pt] 
OR review[pt]))
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